Mirae Asset Global Investments’s Stoke Therapeutics STOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$91.1K Sell
2,785
-194
-7% -$6.23K ﹤0.01% 1253
2026
Q1
$97K Buy
2,979
+203
+7% +$6.66K ﹤0.01% 1188
2025
Q4
$88.1K Buy
2,776
+658
+31% +$19.8K ﹤0.01% 1285
2025
Q3
$49.8K Buy
2,118
+9
+0.4% +$154 ﹤0.01% 1340
2025
Q2
$23.9K Buy
2,109
+322
+18% +$3.06K ﹤0.01% 1371
2025
Q1
$12.9K Buy
1,787
+22
+1% +$205 ﹤0.01% 1444
2024
Q4
$19.5K Buy
+1,765
New +$21.7K ﹤0.01% 1426
2024
Q2
Sell
-90,663
Closed -$728K 2415
2024
Q1
$728K Buy
+90,663
New +$549K ﹤0.01% 1708
2023
Q4
Sell
-146,076
Closed -$576K 2596
2023
Q3
$576K Buy
146,076
+12,478
+9% +$82K ﹤0.01% 1811
2023
Q2
$1.42M Buy
133,598
+41,242
+45% +$439K ﹤0.01% 1383
2023
Q1
$769K Buy
92,356
+741
+0.8% +$6.68K ﹤0.01% 1679
2022
Q4
$846K Sell
91,615
-2,738
-3% -$28.5K ﹤0.01% 1584
2022
Q3
$1.21M Buy
94,353
+13,555
+17% +$216K ﹤0.01% 1383
2022
Q2
$1.07M Buy
+80,798
New +$1.23M ﹤0.01% 1372

Other funds holding STOK

Mirae Asset Global Investments's STOK Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Stoke Therapeutics (STOK) stake by 6.5% in Q2 2026, selling an estimated $6.23K and leaving 2,785 shares worth $91.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1253.

Mirae Asset Global Investments first reported a position in STOK in Q2 2022 and has held it in 14 quarters since. The position peaked at $1.42M in Q2 2023. 20 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Mirae Asset Global Investments held 2,785 shares of Stoke Therapeutics worth $91.1K as of Q2 2026.
  • Mirae Asset Global Investments sold 194 Stoke Therapeutics shares in Q2 2026, an estimated $6.23K.
  • Stoke Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1253 holding.
  • Mirae Asset Global Investments first reported a position in Stoke Therapeutics in Q2 2022 and has held it in 14 quarters since.
  • Mirae Asset Global Investments's Stoke Therapeutics position peaked at $1.42M in Q2 2023.
  • 20 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.